CP
GSK icon

Corbenic Partners’s GSK GSK Stock Holding History

Corbenic Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-160
Closed -$9K – 214
2016
Q2 		$9K Buy
+160
New +$8.43K 0.01% 127
2015
Q4 		– Sell
-1,038
Closed -$50K – 193
2015
Q3 		$50K Buy
1,038
+712
+218% +$37.1K 0.05% 56
2015
Q2 		$17K Hold
326
– – 0.01% 87
2015
Q1 		$19K Hold
326
– – 0.02% 90
2014
Q4 		$17K Buy
326
+246
+308% +$13.8K 0.01% 102
2014
Q3 		$5K Hold
80
– – ﹤0.01% 104
2014
Q2 		$5K Hold
80
– – ﹤0.01% 87
2014
Q1 		$5K Hold
80
– – ﹤0.01% 88
2013
Q4 		$5K Buy
+80
New +$5.19K ﹤0.01% 82

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Corbenic Partners's GSK Position: Q3 2016 in Review

Corbenic Partners sold out of GSK (GSK) in Q3 2016, closing a stake of 160 shares — an estimated $9K sold.

Corbenic Partners first reported a position in GSK in Q4 2013 and held it in 9 quarters. The position peaked at $50K in Q3 2015. 740 funds tracked by Wall St. Rank hold GSK as of Q3 2016.

  • Corbenic Partners reported no remaining GSK position as of Q3 2016 after selling out during the quarter.
  • Corbenic Partners sold 160 GSK shares in Q3 2016, an estimated $9K.
  • Corbenic Partners first reported a position in GSK in Q4 2013 and held it in 9 quarters.
  • Corbenic Partners's GSK position peaked at $50K in Q3 2015.
  • 740 funds tracked by Wall St. Rank held GSK as of Q3 2016.

Based on Corbenic Partners's 13F filing for Q3 2016, filed 27 Oct 2016.